Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global ...

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

Pfizer's acquired products delivered $3.1 billion in Q1 revenue with 22% operational growth. Click here to read why I rate ...

Arvinas (ARVN) stock is in focus as the company and Pfizer (PFE) sell global rights to their breast cancer drug, Verzenio, to ...

Pfizer and Arvinas have landed a buyer for the newly approved breast cancer med Veppanu, selling an exclusive global license to Rigel Pharmaceuticals for $85 million upfront and potentially hundreds ...

Pfizer (PFE +0.85%) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for ...

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...

Arvinas and Pfizer have chosen Rigel Pharmaceuticals to bring their recently approved breast-cancer drug Veppanu to market.

Pfizer (NYSE:PFE) received FDA approval for VEPPANU (vepdegestrant), the first PROteolysis TArgeting Chimera, or PROTAC, ...